Bhutan vs Oman: Tuberculosis patients living with HIV receiving antiretroviral therapy
Bhutan
3 patients
in 2021
Oman
4 patients
in 2021
Bhutan rank
117th
Oman rank
115th
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Bhutan
- Oman
How they compare
Oman currently reports 4 patients against 3 patients in Bhutan, a difference of 1 patients.
That makes Oman's figure about 1.3 times Bhutan's.
The two have swapped places 4 times across 16 shared years of data; in 2003 it was Oman ahead.
Bhutan ranks 117th and Oman ranks 115th of 183 countries.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bhutan | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.17 patients | 7.5 patients | 6.33 patients | Oman |
| 2010s | 3.38 patients | 6.38 patients | 3 patients | Oman |
| 2020s | 4.5 patients | 6 patients | 1.5 patients | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Bhutan or Oman?
- Oman, at 4 patients against 3 patients in Bhutan as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Bhutan and Oman?
- 1 patients, with Oman ahead.
- How many years of comparable data are there for Bhutan and Oman?
- 16 years are reported by both, from 2003 to 2021.
- How do Bhutan and Oman rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Bhutan ranks 117th and Oman ranks 115th of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.